Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Galderma S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Galderma S.A. - Product Pipeline Review - 2014', provides an overview of the Galderma S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Galderma S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Galderma S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Galderma S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Galderma S.A.'s pipeline products Reasons to buy - Evaluate Galderma S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Galderma S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Galderma S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Galderma S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galderma S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Galderma S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Galderma S.A. Snapshot 5 Galderma S.A. Overview 5 Key Information 5 Key Facts 5 Galderma S.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Galderma S.A. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Galderma S.A. - Pipeline Products Glance 13 Galderma S.A. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Galderma S.A. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Galderma S.A. - Unknown Stage Pipeline Products 16 Unknown Products/Combination Treatment Modalities 16 Galderma S.A. - Drug Profiles 17 (adapalene + benzoyl peroxide) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ivermectin 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CD-07387 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CD-5789 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CD2475/101 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 resiquimod 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Galderma S.A. - Pipeline Analysis 23 Galderma S.A. - Pipeline Products by Target 23 Galderma S.A. - Pipeline Products by Route of Administration 24 Galderma S.A. - Pipeline Products by Molecule Type 25 Galderma S.A. - Pipeline Products by Mechanism of Action 26 Galderma S.A. - Recent Pipeline Updates 27 Galderma S.A. - Dormant Projects 28 Galderma S.A. - Company Statement 29 Galderma S.A. - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables Galderma S.A., Key Information 5 Galderma S.A., Key Facts 5 Galderma S.A. - Pipeline by Indication, 2014 7 Galderma S.A. - Pipeline by Stage of Development, 2014 8 Galderma S.A. - Monotherapy Products in Pipeline, 2014 9 Galderma S.A. - Combination Treatment Modalities in Pipeline, 2014 10 Galderma S.A. - Partnered Products in Pipeline, 2014 11 Galderma S.A. - Partnered Products/ Combination Treatment Modalities, 2014 12 Galderma S.A. - Phase III, 2014 13 Galderma S.A. - Phase II, 2014 14 Galderma S.A. - Phase I, 2014 15 Galderma S.A. - Unknown, 2014 16 Galderma S.A. - Pipeline by Target, 2014 23 Galderma S.A. - Pipeline by Route of Administration, 2014 24 Galderma S.A. - Pipeline by Molecule Type, 2014 25 Galderma S.A. - Pipeline Products by Mechanism of Action, 2014 26 Galderma S.A. - Recent Pipeline Updates, 2014 27 Galderma S.A. - Dormant Developmental Projects,2014 28 Galderma S.A., Other Locations 30 Galderma S.A., Subsidiaries 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.